Extended Therapeutic Effect of 35kDa Hyaluronan Fragment Injection in Patients With Chronic Pain Caused by Myofascial Pain Syndrome
CompletedNot applicableNCT06444035
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
To verify the efficacy and safety of HA35 in chronic pain management and to further supplement effective treatments for chronic pain, we designed a proof-of-concept clinical study. This study aims to evaluate the 15-day treatment of HA35 on patients with myofascial pain syndrome and to observe the effects for up to 3 months.
Study details
- Official title
- 35kDa Hyaluronan Fragment Injection Treatment Myofascial Pain Syndrome
- Conditions
- Chronic Wound
- Myofascial Pain Syndrome
- Interventions
- Drug: HA35 injection
- Sponsor
- Nakhia Impex LLC
- Start date
- 2024-05-30
- Primary completion
- 2024-10-30
- Sex
- All
- Age range
- from 18 Years to 65 Years
- Results posted
- No results posted in this snapshot
- Countries
- Mongolia
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Male and female, aged 18-65 years old ; * suffering from muscle strain, sprain, fall, wind and other diagnosed as myofascitis in patients with chronic back pain; * the pain reported by the subject should reach level 3 or higher on the digital rating scale of 0-10 ( 0 means no pain, 10 represents the strongest pain imaginable ); * the mental state is good, and the pain level can be evaluated independently; * be able to cooperate with the treatment independently and sign a written consent. Exclusion Criteria: * Previous severe trauma with permanent musculoskeletal dysfunction; * symptomatic lumbar disc herniation with neurological deficits; * specific spinal diseases, including rheumatoid arthritis, ankylosing spondylitis, and osteoporosis; * diagnosed with mental illness; * agree not to sign the written consent; * pregnant, lactating or fertile women; * currently participating ( or participating in the past 30 days ) in research-based treatment or equipment trials.
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT06444035